These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 11736917)

  • 41. Cost effectiveness of continuous terbinafine compared with intermittent itraconazole in the treatment of dermatophyte toenail onychomycosis: an analysis of based on results from the L.I.ON. study. Lamisil versus Itraconazole in Onychomycosis.
    Jansen R; Redekop WK; Rutten FF
    Pharmacoeconomics; 2001; 19(4):401-10. PubMed ID: 11383756
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [The modern approach to the treatment for onychomycosis of hands and feet in the outpatient setting].
    Gerasimchuk EV; Gerasimov VV; Molchanov BA
    Voen Med Zh; 2005 Nov; 326(11):44-5. PubMed ID: 16404907
    [No Abstract]   [Full Text] [Related]  

  • 43. Long-term evaluation of terbinafine 250 and 500 mg daily in a 16-week oral treatment for toenail onychomycosis.
    De Cuyper C
    Br J Dermatol; 1996 Jul; 135(1):156-7. PubMed ID: 8776393
    [No Abstract]   [Full Text] [Related]  

  • 44. Cholestatic jaundice due to terbinafine.
    Dwyer CM; White MI; Sinclair TS
    Br J Dermatol; 1997 Jun; 136(6):976-7. PubMed ID: 9217846
    [No Abstract]   [Full Text] [Related]  

  • 45. Itraconazole pulse therapy vs continuous terbinafine dosing for toenail onychomycosis.
    Kejda J
    Postgrad Med; 1999 Jul; Spec No():12-5. PubMed ID: 10492661
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Intermittent terbinafine for toenail onychomycosis: is it effective? Results of a randomized pilot trial.
    Warshaw EM; Carver SM; Zielke GR; Ahmed DD
    Arch Dermatol; 2001 Sep; 137(9):1253. PubMed ID: 11559235
    [No Abstract]   [Full Text] [Related]  

  • 47. [Diagnosis and treatment of onychomycoses with terbinafine (Lamisil)].
    Baudraz F; Rakosi T
    Rev Med Suisse Romande; 1998 Nov; 118(11):975-9. PubMed ID: 9865129
    [No Abstract]   [Full Text] [Related]  

  • 48. Terbinafine-induced subacute cutaneous lupus erythematosus.
    Brooke R; Coulson IH; al-Dawoud A
    Br J Dermatol; 1998 Dec; 139(6):1132-3. PubMed ID: 9990400
    [No Abstract]   [Full Text] [Related]  

  • 49. Long-term results in patients with onychomycosis treated with terbinafine or itraconazole.
    Heikkilä H; Stubb S
    Br J Dermatol; 2002 Feb; 146(2):250-3. PubMed ID: 11903235
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Terbinafine-induced subacute cutaneous lupus erythematosus.
    McKay DA; Schofield OM; Benton EC
    Acta Derm Venereol; 2004; 84(6):472-4. PubMed ID: 15844640
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of toenail onychomycosis. Prescribing terbinafine to every patient with the condition would be expensive.
    Rose P; Wilson T
    BMJ; 1999 Oct; 319(7218):1197. PubMed ID: 10610152
    [No Abstract]   [Full Text] [Related]  

  • 52. Severe erythema anulare centrifugum-like psoriatic drug eruption induced by terbinafine.
    Wach F; Stolz W; Hein R; Landthaler M
    Arch Dermatol; 1995 Aug; 131(8):960-1. PubMed ID: 7632075
    [No Abstract]   [Full Text] [Related]  

  • 53. Onychomycosis: a new emerging infectious disease in childhood population and adolescents. Report on treatment experience with terbinafine and itraconazole in 36 patients.
    Ginter-Hanselmayer G; Weger W; Smolle J
    J Eur Acad Dermatol Venereol; 2008 Apr; 22(4):470-5. PubMed ID: 18194238
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Serious interaction between warfarin and oral terbinafine.
    Warwick JA; Corrall RJ
    BMJ; 1998 Feb; 316(7129):440. PubMed ID: 9492670
    [No Abstract]   [Full Text] [Related]  

  • 55. Trichophyton rubrum DNA strain switching increases in patients with onychomycosis failing antifungal treatments.
    Gupta AK; Nakrieko KA
    Br J Dermatol; 2015 Jan; 172(1):74-80. PubMed ID: 24903451
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Iontophoretic terbinafine delivery in onychomycosis: questionable nail growth.
    Oon HH; Tan HH
    Br J Dermatol; 2010 Mar; 162(3):699-700. PubMed ID: 20030642
    [No Abstract]   [Full Text] [Related]  

  • 57. Safety of oral terbinafine for toenail onychomycosis.
    Pollak R; Billstein SA
    J Am Podiatr Med Assoc; 1997 Dec; 87(12):565-70. PubMed ID: 9425805
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Continuous terbinafine versus intermittent itraconazole for toenail onychomycosis.
    Warrick D; Church L
    J Fam Pract; 1999 Jul; 48(7):492-3. PubMed ID: 10428238
    [No Abstract]   [Full Text] [Related]  

  • 59. [Terbinafine-induced persistent agueusia: first reported case].
    Schmutz JL; Barbaud A; Tréchot P
    Ann Dermatol Venereol; 2000 Mar; 127(3):341. PubMed ID: 10804319
    [No Abstract]   [Full Text] [Related]  

  • 60. Antifungal Drugs for Onychomycosis: Efficacy, Safety, and Mechanisms of Action.
    Rosen T; Stein Gold LF
    Semin Cutan Med Surg; 2016 Mar; 35(3 Suppl 3):S51-5. PubMed ID: 27074700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.